Sign inJoin waitlistJoin the waitlist

Mohamad Cherry

Program Director · Rutgers Health

Credentials: · · · · · · ·

History

Rutgers Health
Present

University of Oklahoma Health Sciences Center's Stephenson
2005–2008
American University of Beirut Medical Center in Lebanon
2002–2005
Sacre Coeur Hospital-Lebanese University
2001–2002
Stephenson Cancer Center
LEBANESE UNIV SCHOOL OF MED FAC OF MED SCIENCES, BEIRUT
1997–2001
Lebanese University

Research

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study
British Journal of Haematology · 2017 · 71 citations
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Journal of Clinical Oncology · 2023 · 48 citations
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia
American Journal of Hematology · 2019 · 36 citations

GS
George Selby
8 papers
Jennifer Chakrabarty
8 papers
Mohamad Khawandanah
6 papers
Samer Srour
5 papers · 4 as a fellow
Sami Ibrahimi
5 papers · 5 as a fellow
Namali Pierson
4 papers · 3 as a fellow
Sarbajit Mukherjee
4 papers · 4 as a fellow
Teresa Scordino
4 papers
Mohamed Dabaja
3 papers
WK
William Kern
3 papers
Aaron Mansfield
2 papers
AT
Alfonso Tafur
2 papers

Clinical trials

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Principal investigator · Terminated · Phase 2
University of Oklahoma
2009–2014
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Site PI · Recruiting · Phase 2, Phase 3
Moleculin Biotech, Inc.
2025–2030
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Site PI · Recruiting · Phase 1, Phase 2
Sumitomo Pharma America, Inc.
2022–2027
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Site PI · Recruiting · Phase 1, Phase 2
Sellas Life Sciences Group
2021–2027